Human B cells on their route to latent infection - Early but transient expression of lytic genes of Epstein-Barr virus

European Journal of Cell Biology

Volumn 91, Issue 1, 2012, Pages 65-69

  Kalla, Markus ^a   Hammerschmidt, Wolfgang ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Epigenetics; Gene regulation; Herpes viruses; Immune evasion; Latent infection; Lytic infection; Virology

Indexed keywords

BCRF1 PROTEIN; BHRF1 PROTEIN; EPSTEIN BARR VIRUS ANTIGEN 1; IMMEDIATE EARLY PROTEIN BZLF1; INTERLEUKIN 10; MICRORNA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL PROLIFERATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IN VITRO STUDY; LATENT VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; VIRUS ENTRY; VIRUS GENE; VIRUS SURVIVAL;

B-LYMPHOCYTES; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; INTERLEUKIN-10; LYMPHOPROLIFERATIVE DISORDERS; MICRORNAS; VIRUS LATENCY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

EID: 84855910397     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2011.01.014     Document Type: Short Survey

References (46)

1. Altmann M., Hammerschmidt W. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol. 2005, 3:e404.
2. Altmann M., Pich D., Ruiss R., Wang J., Sugden B., Hammerschmidt W. Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14188-14193.
3. Bell M.J., Abbott R.J., Croft N.P., Hislop A.D., Burrows S.R. An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP. J. Virol. 2009, 83:2783-2788.
4. Bergbauer M., Kalla M., Schmeinck A., Gobel C., Rothbauer U., Eck S., Benet-Pages A., Strom T.M., Hammerschmidt W. CpG-methylation regulates a class of Epstein-Barr virus promoters. PLoS Pathog. 2010, 6:e1001114.
5. Boya P., Pauleau A.L., Poncet D., Gonzalez-Polo R.A., Zamzami N., Kroemer G. Viral proteins targeting mitochondria: controlling cell death. Biochim. Biophys. Acta 2004, 1659:178-189.
6. Countryman J., Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:4085-4089.
7. Croft N.P., Shannon-Lowe C., Bell A.I., Horst D., Kremmer E., Ressing M.E., Wiertz E.J., Middeldorp J.M., Rowe M., Rickinson A.B., Hislop A.D. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog. 2009, 5:e1000490.
8. Dirmeier U., Hoffmann R., Kilger E., Schultheiss U., Briseno C., Gires O., Kieser A., Eick D., Sugden B., Hammerschmidt W. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 2005, 24:1711-1717.
9. Dolken L., Malterer G., Erhard F., Kothe S., Friedel C.C., Suffert G., Marcinowski L., Motsch N., Barth S., Beitzinger M., Lieber D., Bailer S.M., Hoffmann R., Ruzsics Z., Kremmer E., Pfeffer S., Zimmer R., Koszinowski U.H., Grasser F., Meister G., Haas J. Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by RISC immunoprecipitation assay. Cell Host Microbe 2010, 7:324-334.
10. Farrell P.J., Rowe D.T., Rooney C.M., Kouzarides T. Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 1989, 8:127-132.
11. Feederle R., Kost M., Baumann M., Janz A., Drouet E., Hammerschmidt W., Delecluse H.J. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 2000, 19:3080-3089.
12. Gires O., Zimber-Strobl U., Gonnella R., Ueffing M., Marschall G., Zeidler R., Pich D., Hammerschmidt W. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997, 16:6131-6140.
13. Hammerschmidt W., Sugden B. Epstein-Barr virus. DNA Replication and Human Disease 2006, 687-705. Cold Spring Harbor Laboratory Press, New York. M.L. DePamphilis (Ed.).
14. Heslop H.E., Slobod K.S., Pule M.A., Hale G.A., Rousseau A., Smith C.A., Bollard C.M., Liu H., Wu M.F., Rochester R.J., Amrolia P.J., Hurwitz J.L., Brenner M.K., Rooney C.M. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
15. Hislop A.D., Ressing M.E., van Leeuwen D., Pudney V.A., Horst D., Koppers-Lalic D., Croft N.P., Neefjes J.J., Rickinson A.B., Wiertz E.J. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J. Exp. Med. 2007, 204:1863-1873.
16. Horst D., van Leeuwen D., Croft N.P., Garstka M.A., Hislop A.D., Kremmer E., Rickinson A.B., Wiertz E.J., Ressing M.E. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J. Immunol. 2009, 182:2313-2324.
17. Kalla M., Schmeinck A., Bergbauer M., Pich D., Hammerschmidt W. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:850-855.
18. Katsumura K.R., Maruo S., Wu Y., Kanda T., Takada K. Quantitative evaluation of the role of Epstein-Barr virus immediate-early protein BZLF1 in B-cell transformation. J. Gen. Virol. 2009, 90:2331-2341.
19. Kelly G.L., Long H.M., Stylianou J., Thomas W.A., Leese A., Bell A.I., Bornkamm G.W., Mautner J., Rickinson A.B., Rowe M. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 2009, 5:e1000341.
20. Kennedy G., Sugden B. EBNA-1, a bifunctional transcriptional activator. Mol. Cell. Biol. 2003, 23:6901-6908.
21. Kieser A. Signal transduction by the Epstein-Barr virus oncogene latent membrane protein 1 (LMP1). Signal Trans. 2007, 7:20-33.
22. Kintner C., Sugden B. Conservation and progressive methylation of Epstein-Barr viral DNA sequences in transformed cells. J. Virol. 1981, 38:305-316.
23. Lacasse J.J., Schang L.M. During lytic infections, herpes simplex virus type 1 DNA is in complexes with the properties of unstable nucleosomes. J. Virol. 2010, 84:1920-1933.
24. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
25. Low M., Hay J., Keir H.M. DNA of herpes simplex virus is not a substrate for methylation in vivo. J. Mol. Biol. 1969, 46:205-207.
26. Mancao C., Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007, 110:3715-3721.
27. Merlo A., Turrini R., Dolcetti R., Martorelli D., Muraro E., Comoli P., Rosato A. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010, 95:1769-1777.
28. Minarovits J. Epigenotypes of latent herpesvirus genomes. Curr. Top. Microbiol. Immunol. 2006, 310:61-80.
29. Moosmann A., Bigalke I., Tischer J., Schirrmann L., Kasten J., Tippmer S., Leeping M., Prevalsek D., Jaeger G., Ledderose G., Mautner J., Hammerschmidt W., Schendel D.J., Kolb H.J. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010, 115:2960-2970.
30. Nachmani D., Stern-Ginossar N., Sarid R., Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009, 5:376-385.
31. Ressing M.E., Horst D., Griffin B.D., Tellam J., Zuo J., Khanna R., Rowe M., Wiertz E.J. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin. Cancer Biol. 2008, 18:397-408.
32. Rickinson A.B., Kieff E. Epstein-Barr virus. Fields Virology 2007, 2655-2700. Lippincott-Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley, D.E. Griffin, M.A. Martin, R.A. Lamb, B. Roizman, S.E. Straus (Eds.).
33. Rowe M., Zuo J. Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microb. Infect. 2010, 12:173-181.
34. Schaefer B.C., Strominger J.L., Speck S.H. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol. Cell. Biol. 1997, 17:364-377.
35. Seto E., Moosmann A., Gromminger S., Walz N., Grundhoff A., Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 2010, 6:e1001063.
36. Sinclair A.J. bZIP proteins of human gammaherpesviruses. J. Gen. Virol. 2003, 84:1941-1949.
37. Skalsky R.L., Cullen B.R. Viruses, microRNAs, and host interactions. Annu. Rev. Microbiol. 2010, 64:123-141.
38. Steven N.M., Annels N.E., Kumar A., Leese A.M., Kurilla M.G., Rickinson A.B. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 1997, 185:1605-1617.
39. Takada K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer 1984, 33:27-32.
40. Takada K., Shimizu N., Sakuma S., Ono Y. Transactivation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 1986, 57:1016-1022.
41. Tovey M.G., Lenoir G., Begon-Lours J. Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 1978, 276:270-272.
42. Wen W., Iwakiri D., Yamamoto K., Maruo S., Kanda T., Takada K. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J. Virol. 2007, 81:1037-1042.
43. Wiesner M., Zentz C., Mayr C., Wimmer R., Hammerschmidt W., Zeidler R., Moosmann A. Conditional immortalization of human B cells by CD40 ligation. PLoS ONE 2008, 3:e1464.
44. Woisetschlaeger M., Jin X.W., Yandava C.N., Furmanski L.A., Strominger J.L., Speck S.H. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3942-3946.
45. Xia T., O'Hara A., Araujo I., Barreto J., Carvalho E., Sapucaia J.B., Ramos J.C., Luz E., Pedroso C., Manrique M., Toomey N.L., Brites C., Dittmer D.P., Harrington W.J.J. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by EBV-mir-BHRF1-3. Cancer Res. 2008, 68:1436-1442.
46. Zeidler R., Eissner G., Meissner P., Uebel S., Tampe R., Lazis S., Hammerschmidt W. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997, 90:2390-2397.